Streetbeat News

Products Services

OCGN

Ocugen's stock price increased following the announcement that the Data and Safety Monitoring Board approved proceeding with the medium dose of OCU410 in the Phase 1/2 ArMaDa clinical trial's dose-escalation phase.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 11:18 am

CADL

Candel Therapeutics' shares are experiencing an uptrend following the announcement of positive interim data from a phase 2 clinical trial of CAN-2409 for treating non-metastatic prostate cancer.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 11:12 am

NTRA

Natera announced results from the Phase 3 IMvigor011 trial in muscle-invasive bladder cancer, showing patients who remained Signatera MRD-negative post-surgery had 100% overall survival at 12 months. The data suggests these patients might avoid adjuvant treatment.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 11:04 am

CNI

Canadian National Railway Company (CNI) is advancing its decarbonization efforts by acquiring an EMD mainline hybrid locomotive from Progress Rail. This move is part of CNI's commitment to reducing its carbon footprint and enhancing sustainability in its operations.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 11:03 am

LH

Labcorp has launched Labcorp Plasma Detect, a new solution for Molecular Residual Disease (MRD) clinical research, enhancing its precision oncology offerings. This addition builds on two existing liquid biopsy platforms, Labcorp Plasma Focus and Labcorp Plasma Complete, developed by PGDx, a Labcorp company. All solutions are performed in PGDx's CAP-accredited and CLIA-certified laboratory in Baltimore.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 11:02 am

AZN

AstraZeneca announced that its drug Imfinzi significantly improved overall survival and progression-free survival in patients with limited-stage small cell lung cancer in the ADRIATIC Phase 3 trial.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 10:51 am

BDX

Becton, Dickinson (BDX) announced the global commercial release of new BD FACSDiscover S8 Cell Sorters, featuring BD CellView Image Technology and BD SpectralFX Technology. These technologies, which were highlighted on the cover of Science journal in 2022, aim to enhance research in fields such as cell biology, cancer research, and immunology by providing more access, options, and flexibility for real-time imaging and spectral flow cytometry experiments. The release includes three- and four-laser versions, complementing the previously launched five-laser instrument.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 10:49 am

SHEL

Shell plc (NYSE:SHEL) updated its Q1 FY24 operational outlook, indicating lower LNG trading results but improved production and refinery utilization. Integrated Gas production is expected to be 960-1,000 thousand boe/d, with LNG liquefaction volumes at 7.2-7.6 MT. Upstream production guidance is narrowed to 1,820-1,920 thousand boe/d, with significant exploration write-offs in Albania. Marketing sales volume guidance is slightly reduced, while Chemicals & Products sees increased refinery and chemicals utilization. Q4 FY23 revenue was $78.73 billion, below consensus, but adjusted earnings per ADS exceeded expectations. SHEL shares rose 0.41% in premarket trading.

Portfolio Pulse from Lekha Gupta

April 05, 2024 | 10:45 am

AAPL

SSNLF

Samsung Electronics (OTC:SSNLF) forecasts a significant first-quarter operating profit increase, expecting a 931% jump from the previous year due to recovering chip prices. This contrasts with Apple Inc. (NASDAQ:AAPL), which anticipates its first revenue drop in a decade, attributed to declining iPhone sales and challenges in China. Despite positive guidance, Samsung shares fell by 1.3%, with investors awaiting further details on its high-end memory chip business. The rise in chip prices, driven by demand for AI applications, has boosted Samsung's shares by 34% over the past year.

Portfolio Pulse from Benzinga Neuro

April 05, 2024 | 10:32 am

LVS

Las Vegas Sands has announced planned design and program enhancements to Marina Bay Sands, signaling a significant investment in the property's future. This move is expected to enhance the visitor experience and potentially increase revenue for the company.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 10:22 am